

ESPS Peer-review Report

Name of Journal: World Journal of Radiology

ESPS Manuscript NO: 7637

Title: Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters

Reviewer code: 00291409

Science editor: Wen, Ling-Ling

Date sent for review: 2013-11-27 21:38

Date reviewed: 2014-01-16 09:56

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This review article summarizes the clinical use of bone targeting alpha-emitters for cancer treatment. ²²³RaCl₃ is an important drug for radionuclide therapy, and an review article like this is timely and should attract high interests. The reviewer suggests the acceptance of the paper with a minor revision.

1) Language issues: page 3, “?-emitters” page 4, “high-linear energy-transfer (LET) radiation”, Page 10, “US Food and Drug Administration (FDA)” LFDA and ET were already defined previous context. Page 8, “Alpharadin”, no definition of this. It would be better to just use “Xofigo?”. Page 5, “faeces” and page 7, “demonstrated” are typos. 2) It would be helpful to add some information on the production and availability of ²²³Radium chloride